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diabetes researchers who need to classify patients’ renal impairment stage in the 
absence of detailed eGFR data.
PRM2
CoMPaRison of iRRitable bowel syndRoMe with ConstiPation 
and ChRoniC ConstiPation Patient identifiCation Utilizing 
adMinistRative ClaiMs-based algoRithMs, Modified RoMe iii 
diagnostiC CRiteRia, and Patient-RePoRted PhysiCian diagnoses
Buono J.L.1, Stephenson J.J.2, Spalding W.M.3, Cai Q.2, Tan H.2, Carson R.T.1, Doshi J.A.4
1Forest Research Institute, Inc., a subsidiary of Actavis plc, Jersey City, NJ, USA, 2HealthCore Inc., 
Wilmington, DE, USA, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 4University of 
Pennsylvania, Philadelphia, PA, USA
Objectives: Given the lack of specific ICD-9 codes, no definitive method exists for 
identifying irritable bowel syndrome with constipation (IBS-C) and chronic constipa-
tion (CC) patients in administrative claims. This study compared patients identified 
as having IBS-C and CC through claims-based algorithms with modified Rome III 
criteria and patient-reported physician diagnoses. MethOds: Consenting patients 
aged ≥ 18 years identified from the HealthCore Integrated Research Database as 
having IBS-C (≥ 1 IBS claim and ≥ 2 constipation claims or ≥ 1 constipation claim 
and ≥ 1 constipation-related pharmacy claim) or CC (≥ 2 constipation claims ≥ 90 
days apart or ≥ 1 constipation claim and ≥ 1 constipation-related pharmacy claim 
≥ 90 days apart and no IBS claims) completed a cross-sectional survey that included 
questions pertaining to IBS-C/CC symptoms based on modified Rome III criteria and 
patient self-report of IBS-C and CC physician diagnoses to confirm claims-based 
diagnoses. Results: Among 236 claims-based IBS-C patients, 22% met Rome III 
IBS-C criteria and 43% reported being told by a physician they had IBS-C. In addi-
tion, 33% of claims-based IBS-C patients reported being told by a physician they 
had CC. Among 456 claims-based CC patients, 27% met Rome III CC criteria and 39% 
reported being told by a physician they had CC. However, 38% of claims-based CC 
patients met Rome III criteria for IBS-C and 18% reported being told they had IBS-C. 
Patients who did and did not meet Rome III criteria had similar demographic and 
clinical characteristics. cOnclusiOns: A majority of patients identified as having 
IBS-C and CC via claims did not meet Rome III criteria. There was greater agreement 
between claims-based criteria and patient-reported physician diagnoses than Rome 
criteria. Our findings suggest that patients identified through claims may have been 
asymptomatic at the time of the survey, and those identified as CC patients may be 
IBS-C patients who never received an IBS claim.
PRM3
PsyChoMetRiC validation of PeRfoRManCe oUtCoMes (PeRfos) foR Use 
with hiP fRaCtURe (hf) PoPUlations
Gentile B.1, Ballinger R.S.2, Doll H.A.2, Bush E.N.3
1ICON, San Francisco, CA, USA, 2ICON, Oxford, UK, 3Eli Lilly, Indianapolis, IN, USA
Objectives: The measurement properties of three PerfOs [Timed Up-and-Go (TUG), 
4-Step Stair Climb (4SC) and Repeated Chair Stands (RCS, in two versions with arms 
folded, RCS-A, or arm rests, RCS-B)] were evaluated in hip fracture (HF) surgery 
patients. MethOds: Patients were recruited from 11 clinical sites across 6 US states. 
Participants visited sites at designated time points after HF surgery when patient 
reported outcome (PRO) measures, patient- and clinician-reported global concept 
items (GCI), and PerfOs were administered. PerfOs were scored as time (seconds, s) 
to complete each test. PerfO measurement properties evaluated included: reliability 
(inter-rater, test-retest), construct validity (known-groups, convergent/divergent), 
ability to detect change, minimal important difference (MID) and responder defi-
nitions. Results: Data were recruited from 75 patients (mean age 79.64, SD 6.83 
years; 68.0% female) at baseline; from 68 and 66 at visits 2 and 3. Inter-rater (ICCs: 
0.87 to 0.97) and test-retest (ICCs: 0.91-0.95) reliability was excellent across the 
PerfOs. Known-groups validity: Those without an assistive device had quicker mean 
completion times for all PerfOs but the RCS-A. In addition, TUG times were shorter 
for patients with high versus low SF-12 physical component summary (PCS) scores 
(p = .009). Convergent/divergent validity: the TUG, RCS-B, and 4SC demonstrated 
moderate correlations with the SF-12 PCS (rs ranged -0.227 to -0.449), and stronger 
correlations with the individual physical dimensions than the mental component 
(MCS) and dimension scores. Ability to detect change: patients demonstrated sig-
nificant changes in PerfOs from baseline to Visit 2 for the RCS-B (p = 0.030) and 4SC 
(p = 0.034). MIDs ranging from 1.5s (4SC) to 6.0s (TUG) were found. Based on Best 
Cut Points (BCP) of one-point change in clinician GCIs and values of minimal detect-
able change (MDC90), responder definitions between 2.0s (4SC) and 3.5s (TUG) are 
recommended. cOnclusiOns: Overall, the three PerfOs demonstrated adequate 
psychometric properties.
PRM4
getting the fUll PiCtURe: the iMPoRtanCe of exRaPolating beyond 
the data
Al-Mutairi R., Rittenhouse B.
MCPHS University, Boston, MA, USA
Objectives: Clinical assessments with a limited time horizon for data collection 
are typical. One example is a (now dated) 10-year study of statin therapy by Pharaoh 
& Hollingsworth, 1996 (P & H). Gray (2011) suggests that this study likely under-
estimates the effect of the intervention by limiting its time horizon. We explore 
this suggestion as a methodological point. MethOds: Using life table methods we 
analyzed one cohort from the P & H publication for which data were reported suffi-
ciently (50-year old men with pre-existing CHD) and compared their limited horizon 
analysis with one which extrapolates until the cohort lives out its life expectancy 
under each treatment alternative. Because of the lack of longer term data, assump-
tions need to be employed in order to extend the results (e.g. the treatment effect 
persists, fully, partially, at different levels, or not at all). Results: We replicated the 
P & H 10-year horizon that indicated a treatment/no treatment mean life expectancy 
difference of 0.071 life years (LYs). Assuming a fully persistent treatment effect over 
lifetimes, this increased to 2.35 LYs in the extrapolation, clearly sufficiently differ-
labeled “new drug,” “old drug,” or “no drug”: non-fatal stroke, non-fatal myocar-
dial infarction (MI), cardiovascular death, minor bleeding, major bleeding, bleeding 
death, and need for therapeutic monitoring. We estimated preference weights and 
maximum acceptable risks. Results: A total of 341 patients and 352 individuals 
from the general population completed the questionnaire. On average, patients per-
ceived a 1% increased risk of a fatal bleeding equivalent to a 2% increase in non-fatal 
MI, a 3% increase in non-fatal stroke, a 3% increase in cardiovascular death, a 6% 
increase in major bleeding, or a 16% increase in minor bleeding. As compared to the 
patients, the general population had similar preferences except that they perceived 
a 3% increase in non-fatal MI or a 13% increase in minor bleeding equivalent to a 
1% increase in risk of bleeding death. Patients were less likely to choose “no drug” 
(odds ratio, 0.72; 95% confidence interval, 0.61- 0.84) or “old drug” (odds ratio, 0.86; 
95% confidence interval, 0.81-0.93) than “new drug.” The general population sample 
was indifferent to the drug labels. cOnclusiOns: Patients and the general popu-
lation had similar relative preferences for anticoagulant treatment outcomes but 
were more likely to choose “new drug,” irrespective of its relative benefits and risks.
PP4
MeasURing tReatMent PRefeRenCes of Patients diagnosed with 
idioPathiC PUlMonaRy fibRosis Using best-woRst sCaling
Camponeschi G.F.1, Bridges J.F.2, Danoff S.K.1, Richardson B.1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, 
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Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare, degenerative disease. 
While recently approved therapies provide hope, research is needed to assess 
the value of treatment benefits and risks. This study sought to develop and test 
a patient-centered survey instrument to value the benefits and risks of IPF thera-
pies. MethOds: Using patient and stakeholder engagement, researchers developed 
a survey instrument for measuring the treatment preferences of IPF patients. This 
led to developing a novel best-worst scaling instrument to assess six treatment 
attributes, each defined across three levels, including lung function, shortness of 
breath, persistent cough, gastrointestinal problems, skin problems and risk of liver 
toxicity. Surveys were completed in person or by mail. Patients were shown 18 treat-
ment profiles, created through a main-effect orthogonal experimental design, and 
asked to identify the best and worst aspect of each treatment. Preference weights 
were estimated using a simple score consisting of the number of times a level was 
chosen as best minus the number of times it was chosen as worst and divided by 
the total number of times the level was shown. Conditional on the level chosen in 
the experiment, attribute importance was estimated by comparing the range of 
scores across each attribute, relative to all such deviations. Results: Thirty-five 
participants completed the survey. The most important attribute preferred was 
effect on lung function (35%), followed by risk of gastrointestinal problems (23%), 
risk of liver toxicity (12%) and impact on persistent cough (11%). Patients estimated 
the least important attributes to be risk of skin problems (9%) and impact on short-
ness of breath (9%). cOnclusiOns: This research demonstrates the merits of a 
community-centered approach to survey instrument development to measure 
preferences and illustrates the value in quantifying preferences. Further research 
is needed to assess the generalizability of these findings and the implications for 
decision making.
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Objectives: The validity of diagnosis/procedure coding for determining the severity 
of renal impairment is unknown. This retrospective, observational study developed 
an administrative claims-based algorithm which classified patients with type 2 
diabetes mellitus (T2DM) into renal impairment stages using estimated glomerular 
filtration rate/1.73 sq M by MDRD equation (eGFR) as the measure for renal func-
tion. MethOds: The data source was U.S. administrative claims collected from 
among a sample of 35,624 patients ≥ 18 years of age who, during the period from 
1/1/2012-12/31/2012, had ≥ 1 laboratory result for eGFR, ≥ 2 medical claims with a 
diagnosis code for T2DM, continuous insurance enrollment, and no medical claims 
with a diagnosis/procedure code for type 1 diabetes, gestational diabetes, or preg-
nancy. The sample was divided into two equal random samples: a test set and 
validation set. Among the test set, four logistic regressions were fit modeling Kidney 
Disease Outcomes Quality Initiative-defined renal impairment stages (eGFR < 15, 
< 30, < 60, and < 90) as a function of age, sex, and 25 binary indicators for the presence 
of medical claims with renal impairment-related diagnosis/procedure codes. From 
each regression, a predicted probability was obtained for the validation set and per-
formance of the algorithm was tested (e.g., by ROC analysis) at varying probability 
cutoff classification thresholds. Results: In the validation set, the percentage of 
patients correctly classified by the test set algorithm using a standard probability 
cutoff= 0.5 was 75.9% for eGFR < 90, 82.1% for < 60, 97.3% < 30, and 99.3% for < 15; 
in the test set, these same percentages deviated by less than 1 percentage point. 
Model C-statistics ranged from 0.79 for eGFR < 90 to 0.89 for eGFR < 15. Sensitivity/
specificity varied considerably by selected probability cutoffs. cOnclusiOns: This 
novel, replicable, administrative claims-based algorithm should prove useful to 
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at market entry of each drug of interest and using a sequential propensity score 
matched cohort design. We applied four BRA metrics: number needed to treat and 
number needed to harm (NNT|NNH); incremental net benefit (INB) with maximum 
acceptable risk [MAR], INB with relative-value adjusted life years [RVALYs], and INB 
with quality-adjusted life years [QALYs]. We determined whether and when the 
bootstrapped 99% confidence interval (CI) for each metric excluded zero, indicating 
net favorability of one drug over the other. Results: For rofecoxib, all four metrics 
yielded a negative value, suggesting net favorability of ns-NSAIDs over rofecoxib, 
and the 99% CI for all but the NNT|NNH excluded the null during follow-up. For 
prasugrel, only the 99% CI for INB-QALY excluded the null, but trends in values 
over time were similar across the four metrics, suggesting overall net favorability 
of prasugrel versus clopidogrel. The 99% CI for INB-RVALY and INB-QALY excluded 
the null in the denosumab example, suggesting net favorability of denosumab over 
bisphosphonates. cOnclusiOns: Prospective benefit-risk monitoring can be used 
to determine net favorability of a new drug in electronic healthcare data. In three 
examples, existing BRA metrics produced qualitatively similar results but differed 
with respect to alert generation. INB-QALY produced the most conclusive findings 
across the three examples.
PRM8
Qt PRolongation identifiCation in RetRosPeCtive stUdies
Ye Y., Caffrey A.R.
University of Rhode Island, Kingston, RI, USA
Objectives: To evaluate operational definitions for cardiac events related to QT 
prolongation, such as paroxysmal ventricular tachycardia, ventricular fibrillation 
and flutter, cardiac arrest, and sudden cardiac death, in retrospective studies using 
administrative databases. MethOds: Using PubMed, we searched for studies that 
retrospectively identified cardiac events related to QT prolongation in administra-
tive or claims databases and were published between January 2000 and September 
2014. Selection for full-text review was based on a preliminary review of titles and 
abstracts. Results: Our initial search yielded 988 articles from which five were 
selected for inclusion after full-text review. Case report, clinical trial, congenital long 
QT syndrome, cardiac event not related to QT prolongation, and electrocardiography 
utilization are reasons for exclusion. Seven additional articles were identified from 
the references of these articles. The twelve included articles consist of four cohort 
studies (33%), three case-control studies (25%), three validation studies (25%), and 
two descriptive studies (17%). Nine studies (75%) utilized databases from the United 
States, five (42%) of which used Medicaid data, and three (25%) used European data. 
The most common operation definitions for cardiac events related to QT prolonga-
tion were primary discharge diagnosis of long QT-related cardiac events (75%) and 
sudden cardiac death (25%). The most common administrative codes utilized were 
ICD-9 (83%) and ICD-10 (17%). The most frequently utilized ICD-9 diagnosis code 
was 427.x (100%, cardiac dysrhythmias, ICD-10: I47-49), followed by 426.x (33%, con-
duction disorders, ICD-10: I44-45), and 798.x (33%, sudden death, cause unknown, 
ICD-10: R96). Six studies (50%) reviewed medical records to validate the diagnosis 
codes. Positive predictive values ranged from 77-94% when defining cardiac events 
related to QT prolongation using ICD-9 codes 426.x or 427.x. cOnclusiOns: In 
administrative databases, ICD-9 codes 426.x and 427.x as the principle discharge 
diagnosis or underlying cause of death are commonly used to identify cardiac events 
related to QT prolongation.
PRM9
CoMPaRison of benefit-Risk assessMent Methods foR PRosPeCtive 
MonitoRing of newly MaRketed dRUgs: a siMUlation stUdy
Gagne J.J.1, Najafzadeh M.1, Choudhry N.K.1, Bykov K.2, Kahler K.3, Martin D.P.3, Rogers J.R.2, 
Schneeweiss S.1
1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Brigham and 
Women’s Hospital, Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
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Objectives: We compared benefit-risk assessment (BRA) methods for determining 
whether and when sufficient evidence exists to indicate that one drug is favora-
ble over another in prospective monitoring. MethOds: We simulated prospective 
monitoring of a new drug (A) versus an alternative (B) with respect to two beneficial 
and three harmful outcomes. We generated data for 1,000 iterations of six sce-
narios and applied four BRA metrics: number needed to treat and number needed 
to harm (NNT|NNH); incremental net benefit (INB) with maximum acceptable risk 
(INB-MAR); INB with relative-value adjusted life years (INB-RVALY); and INB with 
quality-adjusted life years (INB-QALY). We determined the proportion of iterations 
in which the 99% confidence interval (CI) for each metric included and excluded the 
null and we calculated mean time-to-alerting. Results: With no true difference 
in any outcome between drugs A and B, the proportion of iterations including the 
null was lowest for INB-RVALY (64%) and highest for INB-QALY (76%). When drug 
A was more effective and the drugs were equally safe, INB-QALY indicated net 
favorability of drug A in 81% of iterations, INB-MAR and INB-RVALY indicated net 
favorability in 79% of iterations, and NNT|NNH indicated net favorability in 72% of 
iterations. When drug A was safer than drug B, NNT|NNH had the highest proportion 
of iterations indicating net favorability of drug A (65%). Mean time-to-alerting was 
similar among methods across the six scenarios. cOnclusiOns: BRA metrics can 
be useful for identifying net favorability when applied to prospective monitoring 
of a new drug versus an alternative. INB-based approaches similarly outperform 
unweighted NNT|NNH approaches.
PRM10
Usage of PRoPensity sCoRe, instRUMental vaRiable, oR MaChine 
leaRning foR Real woRld data analysis
Choi S.
PAREXEL International, Billerica, MA, USA
Objectives: It is essential to reduce potential bias by adjusting for confounders 
when performing real world data analysis. It is informative to investigate usage of 
ent to materially affect ICERs. More conservatively, assuming no treatment effect 
beyond 10-years still resulted in 0.35 life years gained, a significant gain compared to 
the 10-year horizon. Varying assumptions in different ways altered the magnitudes 
of the gains in LYs (and potentially cost-effectiveness), but not the essential conclu-
sions. cOnclusiOns: This research confirms Gray’s suggestion of the importance 
of extending analysis time horizons when differential mortality is observed at the 
end of a study. Under any reasonable assumption applied to the extrapolation, any 
survival difference at end of study must persist to some degree beyond that time 
and therefore add to the treatment benefit observed up to the point of extrapola-
tion. Ignoring the post-study period biases clinical and cost-effectiveness results.
PRM5
CoMPaRing diagnosis-based and PResCRiPtion-based CoMoRbidity 
MeasURes foR PRediCting health seRviCe Utilization and Costs
Gangan N., Banahan B. III
University of Mississippi, University, MS, USA
Objectives: Comorbidity scores are frequently used for controlling confounding in 
observational studies using administrative claims. Several comorbidity measures 
have been developed and evaluated for predicting a variety of outcomes. However, 
scores are often used with outcomes other than those included in validation studies. 
Few publications have compared the performance of different scores in predicting 
different types of outcomes. The objective of the present study was to compare the 
Charlson Comorbidity Index (CCI), a frequently used diagnosis-based comorbidity 
score, and Rx Risk, a prescription-based comorbidity score, as predictors of three 
outpatient outcomes. MethOds: A retrospective analysis was conducted using 
Mississippi Medicaid medical and pharmacy claims data for the period January 2010 
to December 2011. Inclusion criteria were continuous enrolment during the observa-
tion period, not dual-eligible, and having both medical and pharmacy claims in both 
calendar years. CCI scores and Rx Risk Scores were calculated using 2010 claims. 
Scores were evaluated as predictors of outpatient visits, total outpatient costs and 
total pharmacy costs in 2011. Costs were log transformed. A base general linear 
model with age, gender, race and ethnicity was developed. Predictive ability of each 
comorbidity score was measured as the change in R2 when the score was added 
to the base model. Results: R2s for the base model were visits - 0.07, outpatient 
costs - 0.01, and pharmacy costs - 0.03. CCI and Rx Risk improved prediction for visits 
and pharmacy costs (CCI R2s; 0.10, 0.05; Rx Risk R2s; 0.13, 0.07). cOnclusiOns: 
Although CCI is often used for outpatient outcomes, Rx Risk provides a better 
measure of comorbidity when the dependent variables are outpatient utilization or 
costs. The CCI was developed for predicting mortality during hospitalization. These 
results indicate that comorbidity scores developed for predicting outpatient out-
comes would be better for controlling for comorbidity in outpatient based studies.
PRM6
MatChing-adjUsted indiReC tReatMent CoMPaRison and sURvival 
extRaPolation in Radioiodine-RefRaCtoRy diffeRentiated thyRoid 
CanCeR (Rai-RefRaCtoRy dtC)
Tremblay G.1, Holbrook T.2, Milligan G.2, Pelletier C.1
1Eisai, Woodcliff Lake, NJ, USA, 2Adelphi Real World, Manchester, UK
Objectives: Indirect treatment comparisons (ITCs) are an important part of any 
comparative effective demonstration in the absence of head-to-head clinical trials. 
Classic ITCs can lead to biased results due to differences in patient populations and 
trial designs. These differences can be corrected for by using matching-adjusted ITC 
(MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial 
results may be required for economic evaluations. The objective of this research was 
to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using MAIC 
and survival extrapolation techniques. MethOds: Mean overall survival (OS) and 
progression-free survival (PFS) outcomes were estimated by weighting lenvatinib’s 
patient level data based on baseline characteristics from sorafenib phase 3 trial 
using logistic regression. Classic ITC was performed before and after adjustment. 
Extrapolation of OS and PFS was performed using proportional hazard, acceler-
ated time failure, individual parametric models and piecewise models (Royston 
& Parmar). Results were presented as hazard ratios (HR) with confidence intervals 
(CI). Results: Unadjusted ITCs for Lenvatinib vs. placebo were 0.746(0.497; 1.119) 
for OS and 0.213(0.158; 0.288) for PFS. The MAIC provided statistically significant 
estimates of 0.577 (0.347; 0.959) for OS and 0.170(0.118; 0.254) for PFS vs. placebo. 
Unadjusted ITCs vs. sorafenib were 0.933(0.529; 1.643) and 0.362(0.245; 0.536) respec-
tively for OS and PFS; while MAIC results were 0.721(0.379; 1.373) and 0.325(0.201; 
0.526) respectively for OS and PFS. Survival extrapolation provided estimates of 7.5-
10 month of additional OS gain for Lenvatinib vs. placebo, with the MAIC extrapola-
tion showing the largest gain and a good model fit. cOnclusiOns: This analysis 
demonstrated that in absence of head-to-head trials, MITC offers important meth-
odology to adjust for population and trial differences, especially in orphan diseases 
where limited data are available. MAIC can increase the reliability of comparative 
effectiveness data and support payers decision making.
PRM7
PRosPeCtive benefit-Risk MonitoRing of new dRUgs foR RaPid 
assessMent of net favoRability in eleCtRoniC healthCaRe data
Gagne J.J.1, Bykov K.2, Najafzadeh M.1, Choudhry N.K.1, Martin D.P.3, Kahler K.3, Rogers J.R.2, 
Schneeweiss S.1
1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Brigham and 
Women’s Hospital, Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA
Objectives: Benefit-risk assessment (BRA) methods can combine measures of 
benefits and risks into a single value. We examined BRA metrics for prospective 
monitoring of new drugs in electronic healthcare data. MethOds: Using two 
databases, we emulated prospective monitoring of three drugs versus compara-
tors (rofecoxib vs. non-selective non-steroidal anti-inflammatory drugs [ns-NSAIDs], 
prasugrel versus clopidogrel, and denosumab versus bisphosphonates) beginning 
